HeartBeam Secures $10 Million in Public Offering to Accelerate Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction was completed on April 16, 2026, with support from key stakeholders including ClearCardio(TM), company leadership and institutional investors. The funds will be directed toward commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.

The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

This development matters because it represents a significant step toward making advanced cardiac monitoring accessible outside traditional medical settings. The funding enables HeartBeam to bring its FDA-cleared technology to market, potentially transforming how heart conditions are detected and managed. Portable ECG systems could allow for earlier intervention in cardiac events, improve remote patient monitoring, and reduce healthcare costs associated with hospital visits.

The implications extend to both clinical practice and patient outcomes. By enabling physicians to monitor cardiac health trends and identify acute conditions remotely, this technology could facilitate timely medical interventions that save lives. The expansion of AI capabilities mentioned in the funding allocation suggests further advancements in automated analysis of cardiac data, potentially increasing diagnostic accuracy and efficiency.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer. Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results.